CalciMedica has filed a notice of an exempt offering of securities to raise $10,340,663.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CalciMedica is raising $10,340,663.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Rachel Leheny played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About CalciMedica
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard s Center for Blood Research in Cambridge, MA. Dr. Stauderman s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.
To learn more about CalciMedica, visit http://www.calcimedica.com/
Contact:
Rachel Leheny, Chief Executive Officer
858-952-5500
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.